Myocardial protection with a beta blocker and glycoprotein IIb/IIIa inhibitor during PCI: attractive concept, but limited evidence of benefit.
Leesar
Massoud A
MA
D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage*; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects*; D015415:Biomarkers / Q000097:blood; D003324:Coronary Artery Disease / Q000628:therapy*; D052279:Creatine Kinase, MB Form / Q000097:blood; D004333:Drug Administration Routes; D004359:Drug Therapy, Combination; D006801:Humans; D009203:Myocardial Infarction / Q000201:enzymology / Q000209:etiology / Q000517:prevention & control*; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors*; D012107:Research Design; D013997:Time Factors; D016896:Treatment Outcome
D000319:Adrenergic beta-Antagonists; D015415:Biomarkers; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D052279:Creatine Kinase, MB Form